Sabinsa Corporation's R & D staff have developed and validated an HPLC assay procedure that has recently been approved by the United States Pharmacopeial Convention. As a courtesy, Sabinsa has sent this method to the leading analytical labs that service the dietary supplements industry. "It is part of our ongoing commitment to raise the consciousness and quality of dietary supplement ingredients.
Sabinsa's Selenium SeLECT is currently the focus of a large-scale prostate cancer study funded through the National Institute of Health's (NIH) National Cancer Institute (NCI). It is the only selenium source being administered in the study. A second study recently was undertaken to evaluate selenomethionine's potential role in Alzheimer's patients.
The USP monograph for Selenomethionine is based on Sabinsa's Selenium SeLECT® brand L-(+)-Selenometahionine.